How a bacterial protein helps Group A Streptococcus evade the immune system

Evasion of host immunity by the M protein

NIH-funded research University of California, San Diego · NIH-10879141

This study is looking at how a specific part of the Group A Streptococcus bacteria helps it dodge our immune system, which can lead to serious illnesses, and it aims to find new ways to boost our immune response against these infections, potentially helping patients in the future.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Diego NIH-funded
Lab location1 site (La Jolla, United States)
Project IDNIH-10879141 on NIH RePORTER

What this research studies

This research investigates how the M protein of Group A Streptococcus (GAS) allows the bacteria to evade the immune system, leading to severe diseases and autoimmune conditions. The study focuses on understanding the interactions between the M protein and human immune proteins that prevent effective immune responses. By exploring the variability of the M protein and its binding capabilities, the research aims to identify potential therapeutic targets to enhance immune responses against GAS infections. Patients may benefit from insights that could lead to new treatments for infections caused by this pathogen.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals who have experienced infections caused by Group A Streptococcus or have autoimmune conditions linked to these infections.

Not a fit: Patients with infections caused by other types of bacteria or those without a history of Group A Streptococcus infections may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that enhance the immune response against Group A Streptococcus infections, reducing morbidity and mortality associated with these diseases.

How similar studies have performed: Other research has shown success in targeting bacterial evasion mechanisms, suggesting that this approach may yield valuable insights and potential breakthroughs.

Where this research is happening

La Jolla, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.